Weil Delphine, Levesque Eric, McPhail Marc, Cavallazzi Rodrigo, Theocharidou Eleni, Cholongitas Evangelos, Galbois Arnaud, Pan Heng Chih, Karvellas Constantine J, Sauneuf Bertrand, Robert René, Fichet Jérome, Piton Gaël, Thevenot Thierry, Capellier Gilles, Di Martino Vincent
Hepatology Department, University Hospital Jean Minjoz, 3 bld Fleming, 25030, Besançon, France.
Centre Hépato-Biliaire, University Hospital Paul Brousse, Villejuif, France.
Ann Intensive Care. 2017 Dec;7(1):33. doi: 10.1186/s13613-017-0249-6. Epub 2017 Mar 21.
The best predictors of short- and medium-term mortality of cirrhotic patients receiving intensive care support are unknown.
We conducted meta-analyses from 13 studies (2523 cirrhotics) after selection of original articles and response to a standardized questionnaire by the corresponding authors. End-points were in-ICU, in-hospital, and 6-month mortality in ICU survivors. A total of 301 pooled analyses, including 95 analyses restricted to 6-month mortality among ICU survivors, were conducted considering 249 variables (including reason for admission, organ replacement therapy, and composite prognostic scores).
In-ICU, in-hospital, and 6-month mortality was 42.7, 54.1, and 75.1%, respectively. Forty-eight patients (3.8%) underwent liver transplantation during follow-up. In-ICU mortality was lower in patients admitted for variceal bleeding (OR 0.46; 95% CI 0.36-0.59; p < 0.001) and higher in patients with SOFA > 19 at baseline (OR 8.54; 95% CI 2.09-34.91; p < 0.001; PPV = 0.93). High SOFA no longer predicted mortality at 6 months in ICU survivors. Twelve variables related to infection were predictors of in-ICU mortality, including SIRS (OR 2.44; 95% CI 1.64-3.65; p < 0.001; PPV = 0.57), pneumonia (OR 2.18; 95% CI 1.47-3.22; p < 0.001; PPV = 0.69), sepsis-associated refractory oliguria (OR 10.61; 95% CI 4.07-27.63; p < 0.001; PPV = 0.76), and fungal infection (OR 4.38; 95% CI 1.11-17.24; p < 0.001; PPV = 0.85). Among therapeutics, only dopamine (OR 5.57; 95% CI 3.02-10.27; p < 0.001; PPV = 0.68), dobutamine (OR 8.92; 95% CI 3.32-23.96; p < 0.001; PPV = 0.86), epinephrine (OR 5.03; 95% CI 2.68-9.42; p < 0.001; PPV = 0.77), and MARS (OR 2.07; 95% CI 1.22-3.53; p = 0.007; PPV = 0.58) were associated with in-ICU mortality without heterogeneity. In ICU survivors, eight markers of liver and renal failure predicted 6-month mortality, including Child-Pugh stage C (OR 2.43; 95% CI 1.44-4.10; p < 0.001; PPV = 0.57), baseline MELD > 26 (OR 3.97; 95% CI 1.92-8.22; p < 0.0001; PPV = 0.75), and hepatorenal syndrome (OR 4.67; 95% CI 1.24-17.64; p = 0.022; PPV = 0.88).
Prognosis of cirrhotic patients admitted to ICU is poor since only a minority undergo liver transplant. The prognostic performance of general ICU scores decreases over time, unlike the Child-Pugh and MELD scores, even recorded in the context of organ failure. Infection-related parameters had a short-term impact, whereas liver and renal failure had a sustained impact on mortality.
接受重症监护支持的肝硬化患者短期和中期死亡率的最佳预测指标尚不清楚。
我们在筛选原始文章并由相应作者回复标准化问卷后,对13项研究(2523例肝硬化患者)进行了荟萃分析。终点指标为入住重症监护病房(ICU)期间、住院期间以及ICU幸存者的6个月死亡率。考虑到249个变量(包括入院原因、器官替代治疗和综合预后评分),共进行了301项汇总分析,其中95项分析仅限于ICU幸存者的6个月死亡率。
入住ICU期间、住院期间和6个月死亡率分别为42.7%、54.1%和75.1%。48例患者(3.8%)在随访期间接受了肝移植。因静脉曲张破裂出血入院的患者入住ICU期间死亡率较低(比值比[OR]0.46;95%置信区间[CI]0.36 - 0.59;p < 0.001),而基线序贯器官衰竭评估(SOFA)> 19的患者死亡率较高(OR 8.54;95% CI 2.09 - 34.91;p < 0.001;阳性预测值[PPV]=0.93)。高SOFA不再是ICU幸存者6个月死亡率的预测指标。12个与感染相关的变量是入住ICU期间死亡率的预测指标,包括全身炎症反应综合征(SIRS)(OR 2.44;95% CI 1.64 - 3.65;p < 0.001;PPV = 0.57)、肺炎(OR 2.18;95% CI 1.47 - 3.22;p < 0.001;PPV = 0.69)、脓毒症相关难治性少尿(OR 10.61;95% CI 4.07 - 27.63;p < 0.001;PPV = 0.76)和真菌感染(OR 4.38;95% CI 1.11 - 17.24;p < 0.001;PPV = 0.85)。在治疗方法中,只有多巴胺(OR 5.57;95% CI 3.02 - 10.27;p < 0.001;PPV = 0.68)、多巴酚丁胺(OR 8.92;95% CI 3.32 - 23.96;p < 0.001;PPV = 0.86)、肾上腺素(OR 5.03;95% CI 2.68 - 9.42;p < 0.001;PPV = 0.77)和分子吸附再循环系统(MARS)(OR 2.07;95% CI 1.22 - 3.53;p = 0.007;PPV = 0.58)与入住ICU期间死亡率相关且无异质性。在ICU幸存者中,8个肝肾功能衰竭指标可预测6个月死亡率,包括Child - Pugh C级(OR 2.43;95% CI 1.44 - 4.10;p < 0.001;PPV = 0.57)、基线终末期肝病模型(MELD)> 26(OR 3.97;95% CI 1.92 - 8.22;p < 0.0001;PPV = 0.75)和肝肾综合征(OR 4.67;95% CI 1.24 - 17.64;p = 0.022;PPV = 0.88)。
入住ICU的肝硬化患者预后较差,因为只有少数患者接受肝移植。与Child - Pugh和MELD评分不同,即使在器官衰竭的情况下,一般ICU评分的预后性能也会随时间下降。感染相关参数对死亡率有短期影响,而肝肾功能衰竭对死亡率有持续影响。